Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8528407 | Clinical Therapeutics | 2017 | 15 Pages |
Abstract
After 52 weeks, patients receiving canagliflozin added to background SU had sustained reductions in HbA1c and fasting plasma glucose, without increasing hypoglycemia and body weight; safety findings were generally consistent with the known safety profile of the drug. ClinicalTrials.gov identifier: NCT01032629.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Jean-François MD, CSPQ, FRCPC, John PhD, Stephen E. PhD, Claude MD, FRCP,